Wedbush Maintains Outperform on Ascendis Pharma, Raises Price Target to $202
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has maintained an Outperform rating on Ascendis Pharma (NASDAQ:ASND) and increased the price target from $200 to $202.
December 20, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides maintains a positive outlook on Ascendis Pharma, raising the price target to $202, indicating potential stock appreciation.
The increase in price target by a reputable analyst typically suggests a bullish view on the stock's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100